All In Biotech

Drug Trial Radar · NCT07038005

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SPGL008 Monotherapy for Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Sep 22, 2026

Study completion Jun 8, 2027

Sponsor

Sponsor type
Industry
Collaborators
Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.

Conditions

  • Advanced Malignant Tumors

Interventions

  • SPGL008Drug

    Biological product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: During the first cycle. Each cycle is 21 days
  2. Maximum tolerated dose (MTD)Time frame: During the first cycle. Each cycle is 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.